Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005659700
Fri, 05.12.2025
Eckert & Ziegler SE
Berlin, 5 December 2025. The Supervisory Board of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) has decided to reduce the size of the Executive Board from three to two members as of 1 January 2026. The contract of Frank Yeager, member of the Executive Board and responsible for the Isotope Products segment, will end as planned on 31 December 2 [ … ]
Wed, 03.12.2025
Eckert & Ziegler SE
Berlin, Germany & Seoul, South Korea, 3 December 2025 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) has signed a supply agreement with SK Biopharmaceuticals, a biotech company specializing in research, development, and commercialization of treatments of central nervous system (CNS) disorder, active in the field of radiopharma and based in [ … ]
Thu, 13.11.2025
Eckert & Ziegler SE
3rd quarter of 2025:
Sales of €75.3 million (previous year: €70.1 million)
EBIT before special items of €15.4 million (previous year: €14.2 million)
Net income of €8.5 million (previous year: €5.3 million)
First 9 months of 2025:
Sales of €224.1 million (previous year: €215.5 million)
EBIT before special items of €50.8 million (previous year: [ … ]
Fri, 19.09.2025
Eckert & Ziegler SE
Berlin, 19 September 2025. Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler), a leading provider of isotope technology for nuclear medicine and radiopharmaceutical applications, has received marketing authorization in Japan from Japan’s Ministry of Health, Labour and Welfare (MHLW) for its GalliaPharm® 68Ge/68Ga Radionuclide Generator, t [ … ]
Tue, 09.09.2025
Eckert & Ziegler SE
Berlin, 9 September 2025. Eckert & Ziegler SE (ISIN DE0005659700), a leading supplier of isotope technology components for nuclear medicine and measurement technology, will be rated by the Hamburg-based private bank Joh. Berenberg, Gossler & Co. KG from now on. In their initial study, the analysts issue a “Buy” recommendation with a price t [ … ]
Fri, 08.08.2025
Eckert & Ziegler SE
2nd Quarter 2025:
Sales: € 80.6 Mio. million (PY: € 77.8 million)
EBIT before special items: € 19.2 million (PY: € 17.5 million)
Net income: € 11,7 million (PY: € 9.5 million)
1st Half Year 2025:
Sales: € 148.8 million (PY: € 145.4 million)
EBIT before special items: € 35.4 million (PY: € 32.5 million)
Net income: € 21.4 million (PY: € 18.0 m [ … ]
Tue, 05.08.2025
Eckert & Ziegler SE
Berlin, 5 August 2025. All formal requirements of the stock split resolved by the Annual General Meeting on 18 June 2025 have now been met and the timeline for implementation of this capital measure of Eckert & Ziegler SE (ISIN DE0005659700) on the bank side is set.
Accordingly, the company's shareholders will be entitled to new shares in the r [ … ]
Tue, 29.07.2025
Eckert & Ziegler SE
Berlin, Germany, 29 July 2025. Eckert & Ziegler (ISIN DE0005659700) has entered a Master Service Agreement with Archeus Technologies (Archeus), a company developing multiple differentiated radiopharmaceutical therapies, for contract manufacturing of its novel investigational compound ART-101. The agreement supports Archeus’ upcoming Phase 1 cli [ … ]
Mon, 28.07.2025
Eckert & Ziegler SE
Berlin, July 28, 2025. The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) resolved on June 18, 2025, to increase the share capital using company funds by € 42,343,864 to € 63,515,796. The capital increase was entered in the commercial register on 25 July 2025 and thus became effective. As a result, the company's share capital [ … ]
Tue, 15.07.2025
Eckert & Ziegler SE
Berlin, July 15, 2025. Eckert & Ziegler SE (ISIN DE0005659700) has been recognized by the Berlin Chamber of Industry and Commerce (IHK) for the exceptional quality of its training program for the fourth time in a row. The Berlin-based healthcare company already held the award for “Excellent Training Quality” from 2019 to 2020, from 2021 to 2023 [ … ]
